Skip to main content

Gilead Sciences statistics

  • GILD · Nasdaq
  • Biotechnology
  • S&P 500
$168.08+0.08%Close 13 Nov 2026 · Market value $210.1B

Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.

Valuation

Gilead Sciences is valued at $210.1B on its latest close.

Market value$210.1B
Enterprise value$228.4B
Price / sales6.78
Price / book16.11
EV / EBITDA505.27
EV / sales7.37
Price / free cash flow15.25
Price / free cash flow, own 5-year average12.56
EV / free cash flow16.69
Free cash flow yield6.6%
Dividend yield2.0%

Share price

Latest close$168.08
Day's change+0.1%
52-week high$176.58
52-week low$116.88
From 52-week high−4.8%
Return · 1 month+7.6%
Return · 3 months+17.2%
Return · year to date+36.9%
Return · 1 year+36.2%
Beta · 1 year against the S&P 5000.37
50-day average$155.10
200-day average$141.72
RSI 1459.3
Average volume · 20 sessions6.6M

Margins and returns

For fiscal 2025, as filed.

Gross margin78.8%
Operating margin34.0%
Net margin28.9%
Free cash flow margin32.1%
Return on equity40.5%
Return on assets14.8%
Return on invested capital20.4%
Return on invested capital, 5-year average12.0%
Return on capital employed21.3%
Stock-based compensation / revenue3.0%

Financial position

At the end of fiscal 2025.

Cash and equivalents$7.56B
Total debt$25.54B
Net debt$17.91B
Current ratio1.55
Quick ratio0.95
Debt / equity1.13
Net debt / EBITDA1.40
Interest coverage9.79

Growth

Revenue, latest quarter on a year+6.8%
Revenue, twelve months on a year+6.5%
EPS, latest quarter on a year−20.2%
EPS, twelve months on a year−148%
Revenue, 5-year compound+3.6%
Revenue, 10-year compound−1.0%
Net income, 5-year compound+133%
Free cash flow, 5-year compound+4.7%
EPS, 5-year compound+134%

Shares and dividends

For fiscal 2025, as filed.

Diluted shares1.3B
Shares outstanding, 5-year compound−0.1%
Net share repurchases$1.51B
Dividends per share$3.16
Dividend payout47.0%

Taxes

For fiscal 2025, as filed.

Income tax expense$1.29B
Effective tax rate13.1%

GILD in the terminal

Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.